An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed. Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management Alhomoud 2024 Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Wiley Online Library Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Development of a Long Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP 1R Agonists for the Treatment of Obesity Bioconjugate Chemistry Can amylin weight loss drugs compete in a world of GLP 1s? C&EN Global Enterprise